ITM Solucin GmbH
Clinical Trials
24
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (24 trials with phase data)• Click on a phase to view related trials
A trial to determine the dose, and evaluate the safety and pharmacokinetics of lutetium Lu 177 edotreotide in children with somatostatin receptor-positive (SSTR+) tumors
- Conditions
- Pediatric patients two years of age and above with somatostatin receptor positive (SSTR-positive) solid tumors or lymphoma, recurrent/refractory to at least one prior line of therapy
- First Posted Date
- 2025-03-19
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- ITM Solucin GmbH
- Target Recruit Count
- 12
- Registration Number
- 2024-512831-66-00
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy
🇪🇸Hospital Universitari Vall D Hebron, Barcelona, Spain
🇪🇸Hospital General Universitario Gregorio Maranon, Madrid, Spain
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
- Conditions
- Neuroendocrine Tumors
- Interventions
- Drug: 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRTDrug: CAPTEM (Capecitabine and Temozolomide)Other: Amino-Acid SolutionDrug: FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- ITM Solucin GmbH
- Target Recruit Count
- 259
- Registration Number
- NCT04919226
- Locations
- 🇺🇸
Stanford Cancer Center, Palo Alto, California, United States
🇺🇸University of Colorado Hospital, Nuclear Medicine, Aurora, Colorado, United States
🇺🇸H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
- Conditions
- Neuroendocrine Tumors
- Interventions
- First Posted Date
- 2017-02-09
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- ITM Solucin GmbH
- Target Recruit Count
- 309
- Registration Number
- NCT03049189
- Locations
- 🇺🇸
Banner Health d.b.a. Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸Moffitt Cancer Center & Research Institute, Tampa, Florida, United States